A CTX-M extended-spectrum β-lactamase in Pseudomonas aeruginosa and Stenotrophomonas maltophilia

References

1. al Naiemi N. A., Duim B., Savelkoul P. H. M., Spanjaard L., de Jonge E., Bart A., Vandenbroucke-Grauls C. M., de Jong M. D. 2005; Widespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiology. J Clin Microbiol 43:4862–4864 [CrossRef]
   [Google Scholar]
2. Bonnet R. 2004; Growing group of extended-spectrum β -lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 48:1–14 [CrossRef]
   [Google Scholar]
3. Bonnet R., Dutour C., Sampaio J. L. M., Chanal C., Sirot D., Labia R., De Champs C., Sirot J. 2001; Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly. Antimicrob Agents Chemother 45:2269–2275 [CrossRef]
   [Google Scholar]
4. Bradford P. A. 2001; Extended-spectrum β -lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933–951 [CrossRef]
   [Google Scholar]
5. Eckert C., Gautier V., Arlet G. 2006; DNA sequence analysis of the genetic environment of various bla _CTX-M genes. J Antimicrob Chemother 57:14–23
   [Google Scholar]
6. Livermore D. M. 1991; β -Lactamases of Pseudomonas aeruginosa . Antibiot Chemother 44:215–220
   [Google Scholar]
7. Matsumoto Y., Ikeda F., Kamimura T., Yokota Y., Mine Y. 1988; Novel plasmid-mediated β -lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother 32:1243–1246 [CrossRef]
   [Google Scholar]
8. Nagano N., Nagano Y., Cordevant C., Shibata N., Arakawa Y. 2004; Nosocomial transmission of CTX-M-2 β -lactamase-producing Acinetobacter baumannii in a neurosurgery ward. J Clin Microbiol 42:3978–3984 [CrossRef]
   [Google Scholar]
9. NCCLS 2005 Performance standards for antimicrobial susceptibility testing; 15th informational supplement M100–S15 Wayne, PA: National Committee for Clinical Laboratory Standards;
   [Google Scholar]
10. Paterson D. L., Bonomo R. A. 2005; Extended-spectrum β -lactamases: a clinical update. Clin Microbiol Rev 18:657–686 [CrossRef]
    [Google Scholar]
11. Pitout J. D. D., Nordmann P., Laupland K. B., Poirel L. 2005; Emergence of Enterobacteriaceae producing extended-spectrum β -lactamases (ESBLs) in the community. J Antimicrob Chemother 56:52–59 [CrossRef]
    [Google Scholar]
12. Ramadan M. A., Tawfik A. F., Shibl A. M. 1995; Effect of β -lactamase expression on susceptibility of local isolates of Enterobacter cloacae , Serratia marcescens and Pseudomonas aeruginosa to β -lactam antibiotics. Chemotherapy 41:193–199 [CrossRef]
    [Google Scholar]
13. Relman D. A., Schmidt T. M., MacDermott R. P., Falkow S. 1992; Identification of the uncultured bacillus of Whipple's disease. N Engl J Med 327:293–301 [CrossRef]
    [Google Scholar]
14. Sirot D., Sirot J., Labia R., Morand A., Courvalin P., Darfeuille-Michaud A., Perroux R., Cluzel R. 1987; Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae : identification of CTX-1, a novel β -lactamase. J Antimicrob Chemother 20:323–334 [CrossRef]
    [Google Scholar]
15. Walsh T. R., MacGowan A. P., Bennett P. M. 1997; Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia . Antimicrob Agents Chemother 41:1460–1464
    [Google Scholar]
16. Weldhagen G. F., Poirel L., Nordmann P. 2003; Ambler class A extended-spectrum β -lactamases in Pseudomonas aeruginosa : novel developments and clinical impact. Antimicrob Agents Chemother 47:2385–2392 [CrossRef]
    [Google Scholar]